ODT Odonate Therapeutics, Inc. gains 29% Jan 19, 2021

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.http://www.priceseries.com/trade/ODT-Odonate-Therapeutics-Inc-stock-gains-29-percent-a-Trade-Record-by-priceSeries-2020122220210119.html